SRC and ovarian carcinoma: We previously reported that collagen type XI alpha 1 (COL11A1) confers cisplatin resistance to ovarian cancer cells through activation of Src-Akt-NFkB signaling to upregulate the expression of inhibitor of apoptosis proteins (IAPs) as well as by inducing a metabolic switch that prefers fatty acid metabolism [8,9].